United Therapeutics (UTHR) AI Stock Analysis

• Market Cap: $13.82B
• Dividend Yield: N/A
• Average Volume (3M): 515.89K
• Price to Earnings (P/E): 12.2
• Beta (1Y): 0.48
• Revenue Growth: 19.85%
• EPS Growth: 21.16%
• Country: US
• Employees: 1,305
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 6.63
• Shares Outstanding: 45,106,625
• 10 Day Avg. Volume: 360,686
• 30 Day Avg. Volume: 515,893
• PEG Ratio: 4.43
• Price to Book (P/B): 1.96
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 11.91
• Enterprise Value/Market Cap: 0.85
• Enterprise Value/Revenue: 1.04
• Enterprise Value/Gross Profit: 4.40
• Enterprise Value/Ebitda: 1.92
• 1Y Price Target: $383.00
• Price Target Upside: 25.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12

• Rating: 78 Outperform
• Price Target: $340.00 ▲(10.96%Upside)

United Therapeutics' stock is supported by strong financial performance and positive earnings call outcomes, reflecting robust revenue growth and strategic investments. While technical indicators are mixed, the reasonable valuation adds to the investment appeal. The stock's overall score is slightly moderated by competitive pressures and technical resistance levels.

Positive Factors

Commercial Strategy

UTHR's established commercial footprint, longstanding relationships with key physicians/target prescribers, and proactive contracting efforts/favorable positioning with payers should help mitigate potential competitive pressures for the Tyvaso franchise.

Growth Potential

There is still meaningful growth potential for the Tyvaso franchise in PH-ILD, which should continue to support the base business, with longer-term upside potential from IPF.

Therapeutic Synergy

UTHR offers a whole solution of prostacyclin (IV, SC, nebulizer, DPI, oral) for PAH patients, creating therapeutic synergy when patients need to switch modalities.

Negative Factors

Competition

Total Tyvaso franchise revenue forecasts have been trimmed by 4% to account for potentially greater competition.

Competitive Pressures

MEDACorp KOLs seem to gravitate towards the convenience advantage of 1x-daily dosing potential of TPIP vs. UTHR's 4x daily approach with Tyvaso, which may drive patient switching in the PAH / PH-ILD space.

Potential Risks

INSM's TPIP results reflect a key potential longer-term risk to UTHR's PAH franchise, and potentially PH-ILD as well.

United Therapeutics Business Overview & Revenue Model

Company Description

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

How the Company Makes Money

United Therapeutics generates revenue through the sale of its pharmaceutical products, primarily targeting treatments for pulmonary arterial hypertension (PAH) and certain cancers. The company earns money by commercializing its proprietary drugs, such as Remodulin, Tyvaso, and Orenitram, which are sold to healthcare providers and patients worldwide. Additionally, United Therapeutics benefits from government contracts, collaborations, and partnerships that support research and development initiatives. The company also invests in expanding its product line through continuous innovation and clinical trials, which can lead to new approvals and increased market share, further driving revenue growth.

United Therapeutics Financial Statement Overview

Summary

United Therapeutics exhibits a strong financial position with impressive growth and profitability metrics. The income statement reflects robust revenue and profit margins, while the balance sheet is characterized by low leverage and high equity ratios, indicating financial stability. Cash flow generation is strong, supporting operational and strategic initiatives.

Income Statement

United Therapeutics has demonstrated strong financial performance with a consistent increase in total revenue over multiple years. The TTM revenue growth rate is approximately 4.06%, and the gross profit margin stands at a robust 89.00%. Net profit margin is currently 40.43%, indicating efficient cost management and profitability. EBIT and EBITDA margins are also strong, at 46.87% and 52.21% respectively, reflecting solid operational efficiency.

Balance Sheet

The balance sheet is marked by a strong equity position with an equity ratio of 87.89%, indicating a low reliance on debt. The debt-to-equity ratio is low at 0.03, showcasing financial stability. Return on equity is a healthy 17.79%, reflecting effective use of equity capital in generating profits. However, the relatively low total liabilities suggest limited financial leverage.

Cash Flow

The company has demonstrated positive cash flow metrics with a free cash flow growth rate of 4.45%. The operating cash flow to net income ratio is 1.17, indicating strong cash generation relative to net income. The free cash flow to net income ratio is 0.93, showing efficient translation of earnings into free cash flow. The cash flow is stable and supports the company's operational needs.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.88B	2.33B	1.94B	1.69B	1.48B
Gross Profit	2.57B	2.07B	1.79B	1.56B	1.38B
EBITDA	1.65B	1.39B	1.04B	736.80M	646.30M
Net Income	1.20B	984.80M	727.30M	475.80M	514.80M
Balance Sheet
Total Assets	7.36B	7.17B	6.04B	5.17B	4.62B
Cash, Cash Equivalents and Short-Term Investments	3.27B	2.99B	4.15B	3.58B	2.98B
Total Debt	300.00M	700.00M	800.00M	800.00M	800.00M
Total Liabilities	920.00M	1.18B	1.25B	1.21B	1.22B
Stockholders Equity	6.44B	5.98B	4.80B	3.96B	3.40B
Cash Flow
Free Cash Flow	1.08B	747.60M	663.70M	477.40M	696.40M
Operating Cash Flow	1.33B	978.00M	802.50M	598.20M	755.70M
Investing Cash Flow	417.20M	-719.60M	-811.50M	-486.90M	-738.50M
Financing Cash Flow	-1.25B	-11.90M	75.40M	44.80M	-16.90M

United Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 306.41
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTHR, the sentiment is Positive. The current price of 306.41 is above the 20-day moving average (MA) of 294.94, above the 50-day MA of 300.43, and below the 200-day MA of 332.99, indicating a neutral trend. The MACD of 1.18 indicates Negative momentum. The RSI at 59.28 is Neutral, neither overbought nor oversold. The STOCH value of 81.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UTHR.

United Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXEL	84 Outperform	$12.38B	20.60	30.22%	―	24.49%	244.87%
UTHR	78 Outperform	$13.82B	12.23	19.94%	―	19.85%	21.16%
BMRN	77 Outperform	$11.44B	22.14	9.64%	―	17.99%	152.10%
INCY	73 Outperform	$13.68B	218.72	0.47%	―	17.13%	-88.78%
GMAB	72 Outperform	$14.07B	12.84	22.69%	―	25.11%	46.46%
SMMT	53 Neutral	$20.80B	―	-123.93%	―	―	-99.70%
Sector *	50 Neutral	AU$2.62B	3.32	-57.47%	2.40%	36.73%	13.67%

United Therapeutics Corporate Events

United Therapeutics Shareholders Approve Key Resolutions

On June 26, 2025, United Therapeutics held its Annual Meeting of Shareholders where four key matters were voted on. The shareholders elected directors for a one-year term, approved an advisory resolution on executive compensation, amended the 2015 Stock Incentive Plan, and ratified Ernst & Young LLP as the independent public accounting firm for 2025.

The most recent analyst rating on (UTHR) stock is a Hold with a $319.00 price target. To see the full list of analyst forecasts on United Therapeutics stock, see the UTHR Stock Forecast page.

United Therapeutics Secures $2.5 Billion Credit Facility

On April 25, 2025, United Therapeutics Corporation entered into a Credit Agreement with Wells Fargo and other lenders, establishing an unsecured revolving credit facility of up to $2.5 billion, with the possibility of increasing by an additional $750 million. The agreement allows for refinancing existing debt and supporting general corporate purposes. Concurrently, the company borrowed $200 million to repay its previous 2022 Credit Agreement, which was terminated without penalties.